Wed, Sep 17, 2014, 8:31 AM EDT - U.S. Markets open in 59 mins.

Recent

% | $
Quotes you view appear here for quick access.

Protalix BioTherapeutics, Inc. (PLX) Message Board

  • jrus2010 jrus2010 Jan 6, 2011 8:48 PM Flag

    Teva biosimilar rejection

    In October, Teva's Neutroval was rejected and issued a CRL. This was to be a biosimilar version of Amgen's Neupogen and was produced using traditional expression techniques similar to that used by Amgen. This decision will have implications for PLX's Uplyso, and those who are long should take note in advance of February.

    Cheers

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • If you read the interview in the previous post you may arrive at an entirely different conclusion

    • I dont understand what you are trying to say....The only thing I know is that PLX drug is taking care of hundreds of patients now with no probles, FDA actually approved it for patients due to GENZ problems was it the same with TEVA drug? This is why Teva worked so hard to get a deal with PLX? this is why Huruvits tried to convince the board three times to go with TEVA and not with PFE?

      I really don't understand what you are trying to say....

    • tiptopprinting@sbcglobal.net tiptopprinting Jan 6, 2011 10:02 PM Flag

      so what do you think it means for us?

      do you think they will get favorable result on Feb 25? or another push back like they got last year?

      Thanks in advance for your input

 
PLX
2.45-0.06(-2.39%)Sep 16 4:01 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.